Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by emerald03on Apr 28, 2023 7:08am
82 Views
Post# 35418629

RE:RE:RE:13 going to hold?

RE:RE:RE:13 going to hold?I would base the  proposed rise   that xould be rapid on discounted cash flow in  the not too distant future fiscal years

The cash flow could go towards the region of 50 to 100 million dollars annual for Sirona 

Add on a large anticipated   initial licensing payment that potentially should be tens of millions of dollars in the face of the high quality results and multiple competing companies,

And then add on takeover speculation ,which  the management may be happy to encourage for the right price ,as they are not getting any younger themselves, just like all of us.
Takeover could be no less than 2 to 3 USD ,and we are at 13 cents right now,and could even happen within 12 months ,once the companies have had time to look at the data .
<< Previous
Bullboard Posts
Next >>